site stats

Recursion therapeutics stock

WebJul 13, 2024 · SALT LAKE CITY, July 13, 2024 - Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced its formation of a Therapeutics Advisory Board (TAB), chaired by Joseph Miletich, MD, PhD. … WebMar 28, 2024 · Recursion is the clinical-stage biotechnology company industrializing drug discovery by decoding biology. Enabling its mission is the Recursion OS, a platform built …

Team - Recursion

WebApr 11, 2024 · The 15 analysts offering price forecasts for Recursion Pharmaceuticals, have a median target of 19.93, with a high estimate of 37.00 and a low estimate of 7.00. The median estimate represents a... WebFind the latest Tango Therapeutics, Inc. (TNGX) stock quote, history, news and other vital information to help you with your stock trading and investing. la candela restaurant new bedford ma https://groupe-visite.com

Analysts Are Bullish on These Healthcare Stocks: Stoke …

WebApr 14, 2024 · Esperion Therapeutics Inc (ESPR) stock is trading at $1.21 as of 11:29 AM on Friday, Apr 14, a drop of -$0.14, or -10.37% from the previous closing price of $1.35. The stock has traded between $1.21 and $1.35 so far today. Volume today is light. So far 949,750 shares have traded compared to average volume of 6,452,500 shares. WebApr 5, 2024 · The latest price target for Recursion Pharmaceuticals ( NASDAQ: RXRX) was reported by Needham on Thursday, March 16, 2024. The analyst firm set a price target for 17.00 expecting RXRX to rise to ... WebMar 31, 2024 · RECURSION PHARMACEUTICALS, INC. : Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information Nasdaq: RXRX Nasdaq RECURSION PHARMACEUTICALS, INC. project avatar family

RXRX Recursion Pharmaceuticals Inc. Stock Price & News - WSJ

Category:Recursion Pharmaceuticals Inc (RXRX) AAII Stock Evaluator

Tags:Recursion therapeutics stock

Recursion therapeutics stock

Recursion Pharmaceuticals Proposes $306 Million U.S. IPO

WebApr 10, 2024 · Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral ... WebApr 12, 2024 · Recursion Pharmaceuticals (NASDAQ:RXRX) has filed to raise $306 million in an IPO of its Class A common stock, according to an S-1 registration statement. The firm …

Recursion therapeutics stock

Did you know?

WebApr 11, 2024 · According to analysts, Recursion Pharmaceuticals's stock has a predicted upside of 36.20% based on their 12-month price targets. What analysts cover Recursion Pharmaceuticals? Recursion Pharmaceuticals has been rated by Needham & Company LLC, and SVB Leerink in the past 90 days. Stock Ratings Reports and Tools Apple Meta … WebRecursion Pharmaceuticals Overview Update this profile Founded 2013 Status Public Employees 500 Stock Symbol RXRX Investments 2 Share Price $6.65 (As of Thursday …

WebApr 13, 2024 · Denali Therapeutics (DNLI) In a report released yesterday, Michael Yee from Jefferies maintained a Buy rating on Denali Therapeutics, with a price target of $50.00.The company’s shares closed ... WebMar 16, 2024 · In a report released today, Gil Blum from Needham initiated coverage with a Buy rating on Recursion Pharmaceuticals and a price target of $17.00. The company’s …

WebApr 12, 2024 · 5 analysts have issued 12-month price objectives for Recursion Pharmaceuticals' stock. Their RXRX share price forecasts range from $8.00 to $20.00. On … WebApr 10, 2024 · SVB Securities analyst Mani Foroohar reiterated a Hold rating on Recursion Pharmaceuticals (RXRX - Research Report) on February 27 and set a price target of $9.00. …

WebApr 11, 2024 · Recursion Pharmaceuticals, stock has received a consensus rating of hold. The average rating score is and is based on 5 buy ratings, 10 hold ratings, and 0 sell ratings.

WebGet the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed … la cantera physical therapyWebApr 11, 2024 · According to analysts, Recursion Pharmaceuticals's stock has a predicted upside of 36.20% based on their 12-month price targets. What analysts cover Recursion … la cantera new york and companyWebRani Therapeutics Holdings Inc $4.92 RANI6.29% Kiora Pharmaceuticals Inc $3.30 KPRX0.90% PepGen Inc $11.40 PEPG0.87% BioNTech SE - ADR $128.90 BNTX2.63% Finch Therapeutics Group Inc $0.37... project aware 35 symptoms of menopauseWebApr 12, 2024 · Recursion Pharmaceuticals (NASDAQ:RXRX) has filed to raise $306 million in an IPO of its Class A common stock, according to an S-1 registration statement. The firm is developing treatments for ... project awakening release date pcWebNews Recursion Pharmaceuticals Inc. Significant News Only No significant news for RXRX in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-1.44 Market Cap … project aware educationWebDiscover historical prices for RXRX stock on Yahoo Finance. View daily, weekly or monthly format back to when Recursion Pharmaceuticals, Inc. stock was issued. project aware grant mnWebRecursion Pharmaceuticals is registered under the ticker NASDAQ:RXRX . Their stock opened with $18.00 in its Apr 16, 2024 IPO. Stock Symbol NASDAQ:RXRX Valuation at IPO … project aware men\u0027s shelter